varegacestat
AL102 Small Molecule Target: gamma secretase, Notch pathway
Immunome
Most recent annual filing: 2026-03-15
- IM-1021 ADC interim2026IM-1021 ADC interim, 2026, notable
- IM-1340 IND filingmid-2026IM-1340 IND filing, mid-2026, notable
- Varegacestat MAA filingplanned by end of 2026Varegacestat MAA filing, planned by end of 2026, notable
- IM-1335 IND filinglate 2026IM-1335 IND filing, late 2026, notable
- IM-1617 ADC interim2027IM-1617 ADC interim, 2027, notable
- Varegacestat FDA decisionApr 28, 2027Varegacestat FDA decision, Apr 28, 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (9 active programs)
Technology platforms
HC74
Proprietary topoisomerase 1 inhibitor (TOP1i) payload platform supporting ADC development across oncology targets; paired with proprietary optimized linkers to enable next-generation ADC pipeline
Targets: TOP1
Biotech Distilled coverage (2)
- 2026-08-12 UPDATE: Immunome (IMNM) - The Clock Is Set, and It Runs Long 🔒 Paid
- 2026-06-22 Immunome, Inc. (IMNM) — Scientific Deep Dive for Varegacestat and the HC74 ADC Pipeline 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.